Paper39726468
Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.
García-Méndez JO and 9 others. Cureus, 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients. Papers, record 39726468. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39726468
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36317748 | Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. | Expert Rev Anti Infect Ther | 2022 | https://conductscience.org/library/papers/36317748 | PubMed |
| 2 | 33065103 | Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. | Chest | 2021 | https://conductscience.org/library/papers/33065103 | PubMed |
| 3 | 32020029 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. | Cell Res | 2020 | https://conductscience.org/library/papers/32020029 | PubMed |
| 4 | 32895293 | Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. | Open Heart | 2020 | https://conductscience.org/library/papers/32895293 | PubMed |
| 5 | 32878619 | COVID-19 length of hospital stay: a systematic review and data synthesis. | BMC Med | 2020 | https://conductscience.org/library/papers/32878619 | PubMed |
| 6 | 35870876 | Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. | BMC Infect Dis | 2022 | https://conductscience.org/library/papers/35870876 | PubMed |
| 7 | 34623777 | Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis. | Infect Chemother | 2021 | https://conductscience.org/library/papers/34623777 | PubMed |
| 8 | 32533071 | Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. | J Antibiot (Tokyo) | 2020 | https://conductscience.org/library/papers/32533071 | PubMed |
| 9 | 33723507 | Use of ivermectin in the treatment of Covid-19: A pilot trial. | Toxicol Rep | 2021 | https://conductscience.org/library/papers/33723507 | PubMed |
| 10 | 34181716 | Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/34181716 | PubMed |
| 11 | 32584326 | CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY. | Rev Invest Clin | 2020 | https://conductscience.org/library/papers/32584326 | PubMed |
| 12 | 35325252 | Correction to: Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. | QJM | 2022 | https://conductscience.org/library/papers/35325252 | PubMed |
| 13 | 33361100 | Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. | Eur Respir J | 2021 | https://conductscience.org/library/papers/33361100 | PubMed |
| 14 | 32344460 | The potential for COVID-19 to contribute to compassion fatigue in critical care nurses. | J Clin Nurs | 2020 | https://conductscience.org/library/papers/32344460 | PubMed |
| 15 | 15791519 | Nitazoxanide: a new thiazolide antiparasitic agent. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/15791519 | PubMed |
| 16 | 36066651 | Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. | Eur J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/36066651 | PubMed |
| 17 | 33590901 | Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. | J Med Virol | 2021 | https://conductscience.org/library/papers/33590901 | PubMed |
| 18 | 32725536 | A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. | Infect Dis Ther | 2020 | https://conductscience.org/library/papers/32725536 | PubMed |
| 19 | 34145166 | Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. | Am J Ther | 2021 | https://conductscience.org/library/papers/34145166 | PubMed |
| 20 | 33067035 | Coagulation and anticoagulation in COVID-19. | Blood Rev | 2021 | https://conductscience.org/library/papers/33067035 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| FGB | 2244 | PubTator's text mining | https://conductscience.org/library/genes/2244 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39726468
GET https://conductscience.org/api/papers/v1/39726468/references?page=2